Most solid tumours will prove fatal if they are not treated with surgery and/or radiotherapy and medical therapies. But evidence is building to show that treating the primary may raise the risk of metastatic spread. [more]
Hair loss can be a big concern for many cancer patients undergoing chemotherapy, and according to a recent review of the literature published on the Clinical Journal of Oncology Nursing, «scalp cooling efficacy is dependent [more]
Pembrolizumab is the first drug approved by the U.S. Food and Drug Administration for use based on a biomarker (a specific genetic feature) rather than the location in the body where the tumor originated. The drug is indicated [more]
Engaging the body’s own immune system in controlling cancer has long been an aspiration for cancer researchers and clinicians. This overview looks at progress towards that goal, and how it is changing the paradigm of [more]
Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo Casali, a leading expert, presents an update of the latest evidence on the best way to [more]
Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment.Thus, this Course will be first offered to clinical oncologists involved into the existing networks covering rare adult solid [more]